﻿<?xml version="1.0" encoding="utf-8"?><rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0"><channel><ttl>60</ttl><title>Biostatguide</title><link>http://biostatguide.com</link><lastBuildDate>Tue, 16 Mar 2010 02:10:31 GMT</lastBuildDate><pubDate>Tue, 16 Mar 2010 02:10:31 GMT</pubDate><language>en</language><copyright /><itunes:subtitle> </itunes:subtitle><itunes:author /><itunes:summary /><description /><itunes:owner><itunes:name /><itunes:email>drpramil@gmail.com</itunes:email></itunes:owner><itunes:explicit>no</itunes:explicit><itunes:category text="Arts" /><item><title>Sorafenib in advanced hepatocellular carcinoma-Critique of the NEJM article</title><link>http://biostatguide.com/2009/02/02/sorafenib-in-advanced-hepatocellular-carcinomacritique-of-the-nejm-article.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;P&gt;Hypothesis&lt;BR&gt;Does sorafenib increase the survival in cancer patient with hepatocellular carcinoma?&lt;/P&gt;
&lt;P&gt;Sorafenib- oral multikinase inhibitor of vascular endothelial growth factor receptor, inhibits tumor cell proliferation&lt;/P&gt;
&lt;P&gt;Methods&lt;BR&gt;Study population- patients with advanced hepatocellular carcinoma&lt;BR&gt;None of these people received previous systemic chemotherapy&lt;BR&gt;Used child pugh classification??? Why not MELD score?? This is a definite drawback.&lt;/P&gt;
&lt;P&gt;Study design&lt;BR&gt;Multi center, randomized double blind, placebo controlled&lt;BR&gt;Phase 3 trial&lt;/P&gt;
&lt;P&gt;400 mg daily sorfenib&lt;BR&gt;Placebo&lt;/P&gt;
&lt;P&gt;Designed by Bayer- scary&lt;/P&gt;
&lt;P&gt;Primary outcome&lt;BR&gt;Symptomatic progression&lt;BR&gt;Decrease in 4 or more points from the baseline score on patients response &lt;BR&gt;Death&lt;/P&gt;
&lt;P&gt;Secondary outcome&lt;BR&gt;Time to radiologic progression&lt;/P&gt;
&lt;P&gt;Statistical analysis&lt;BR&gt;Intention to treat analysis- analysis is based on the intention to treat in the beginning&lt;BR&gt;This is to avoid the cross over and drop out effects.&lt;BR&gt;Every one who begins he treatment considered as a part of the trial&lt;/P&gt;
&lt;P&gt;Patients&lt;BR&gt;902 patients’ screened&lt;BR&gt;602 met the eligibility criteria&lt;BR&gt;Overall survival&lt;BR&gt;143 vs 178 in the sorafenidb vs placebo&lt;BR&gt;Total of 321 died&lt;BR&gt;Survival 44%&amp;nbsp; vs 33%&amp;nbsp; sorafenib vs placebo&lt;BR&gt;31% relative risk reduction&lt;BR&gt;Overall survival by cox proportional hazard significant&lt;BR&gt;Radiologic progression was lower in&amp;nbsp; sorafenib group&lt;/P&gt;
&lt;P&gt;Discussion&lt;BR&gt;Bottom line. You don’t have any choice. Take it. &lt;BR&gt;FDA is dragging the foot in approving the cancer drugs, people are fed up&lt;BR&gt;Not a great trial.&lt;BR&gt;Some benefit is definitely there.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;</description><comments>http://biostatguide.com/2009/02/02/sorafenib-in-advanced-hepatocellular-carcinomacritique-of-the-nejm-article.aspx#Comments</comments><guid isPermaLink="false">babe5f33-342b-4cd4-b8e7-879cb9e2affc</guid><pubDate>Tue, 03 Feb 2009 02:47:00 GMT</pubDate></item><item><title>PROVE-IT trial: A critique</title><link>http://biostatguide.com/2009/01/14/proveit-trial-a-critique.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;P&gt;Introduction did not do justice this to article.&amp;nbsp; Authors did a poor job in introduction, Not much information about the previous studies.&lt;BR&gt;&lt;BR&gt;Well planned study.&amp;nbsp; Patient population was selected from 8 different countries and impressive number of 4162 patients.&amp;nbsp; Lot of ineligibility criteria about he previous statin use.&amp;nbsp; A creatinine level of 2.0 is a cut off, why?&amp;nbsp; Every one knows renal insufficiency people are at high risk&lt;BR&gt;&lt;BR&gt;Pravastatin 40mg daily vs atorvastatin 80mg daily&lt;BR&gt;Non-inferiority trial&lt;BR&gt;&lt;BR&gt;10 day course of Gatifloxacin was also mentioned given to the patients. If you are mentioning in the trial, please tell us why?&lt;BR&gt;When will the authors report this?&lt;BR&gt;&lt;BR&gt;Average follow up time 2 years. Not good.&amp;nbsp; 5 years may be better.&lt;BR&gt;&lt;BR&gt;Statistical analysis - Looked at the sample size for 87% power,&amp;nbsp; Please mention which software packet was used for analysis.&amp;nbsp; This is not acceptable.&lt;BR&gt;&lt;BR&gt;Primary endpoint- &lt;BR&gt;Pravastatin group was 26.3%&lt;BR&gt;Atorvostatin was 22.4%&lt;BR&gt;Again primary end point was death&lt;BR&gt;So clearly statistically significant benefit is here.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;One other finding is clearly in favor is the reduction of C reactive protien&lt;BR&gt;base line was 12.1&lt;BR&gt;Pravastatin group it was 2.1&lt;BR&gt;Atorvostatin group it was 1.3&lt;BR&gt;but the dose difference is very significant. Pravastatin 40 vs Atorvostatin 80 mg&lt;BR&gt;&lt;BR&gt;Now let us look at the HDL level&lt;BR&gt;Pravastatin increased HDL by 8.1%&lt;BR&gt;Atorastatin only 6.5%&lt;BR&gt;P value is .001&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Main points&lt;BR&gt;&lt;BR&gt;Lower LDL goal is better.&lt;BR&gt;Reduction of CRP is achieved by any statin.&lt;BR&gt;Is there any benefit in increasing the HDL by drug therpay?- Probably not in this tudy group&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;</description><comments>http://biostatguide.com/2009/01/14/proveit-trial-a-critique.aspx#Comments</comments><guid isPermaLink="false">3dbf648c-eff9-4f9f-966d-fe7108d573a1</guid><pubDate>Thu, 15 Jan 2009 02:47:00 GMT</pubDate></item><item><title>Whats the best way to learn Biostats?</title><link>http://biostatguide.com/2009/01/07/whats-the-best-way-to-learn-biostats.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>everybody asks me this question.&lt;BR&gt;Answer is simple.&lt;BR&gt;&lt;BR&gt;read the journals.&lt;BR&gt;look at the methods section.&lt;BR&gt;&lt;BR&gt;read the critique I post here.</description><comments>http://biostatguide.com/2009/01/07/whats-the-best-way-to-learn-biostats.aspx#Comments</comments><guid isPermaLink="false">da1bf30e-19a2-4911-a830-bbc36e845502</guid><pubDate>Thu, 08 Jan 2009 03:52:00 GMT</pubDate></item><item><title>NY times love affair with R</title><link>http://biostatguide.com/2009/01/07/ny-times-love-affair-with-r.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;P&gt;&lt;BR&gt;All praises for this powerful software.&lt;BR&gt;Future is R according to NYT.&lt;BR&gt;&lt;BR&gt;SAS are they worried?&lt;BR&gt;They should be worried.&lt;BR&gt;&lt;BR&gt;Some guy at SAS compared to R with an aircraft engine wihtout any guarantee.&lt;BR&gt;&lt;BR&gt;he was stupid enough to say that o NY times correspondent.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;</description><comments>http://biostatguide.com/2009/01/07/ny-times-love-affair-with-r.aspx#Comments</comments><guid isPermaLink="false">51779f96-c8cd-4801-8224-3fd2c66305bf</guid><pubDate>Thu, 08 Jan 2009 03:05:00 GMT</pubDate></item><item><title>A 4 year trial of Tiotropium in Chronic Obstructive Pulmonary disease:  A critique of this article. UPLIFT trial</title><link>http://biostatguide.com/2009/01/06/a-4-year-trial-of-tiotropium-in-chronic-obstructive-pulmonary-disease--a-crtique-of-this-article-uplift-trial.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;The authors did a good job in the back ground section describing the previous studies.&amp;nbsp; It would been nicer it they can mention any studies comparing Ipatropium and Titropium&lt;BR&gt;&lt;BR&gt;Methods&lt;BR&gt;Good study design. sample size calculated.Multi center.&amp;nbsp; did not mention the race percentage in the demographic section. Does it matter to the authors?&amp;nbsp; Coe n guys, wake up&lt;BR&gt;Demographic table 45% on anticholinergics. But in page 2 people on other anitchlinergic&amp;nbsp; were excluded?&lt;BR&gt;&lt;BR&gt;smokers changed their pattern during the study. So the result are screwed??&lt;BR&gt;&lt;BR&gt;Over all head to head Tiotropium and Placebo - P value not significant&lt;BR&gt;&lt;BR&gt;Where are the benefits.&lt;BR&gt;significant decrease in exacerbations, hospital admissions.&lt;BR&gt;&lt;BR&gt;Interesting findings&lt;BR&gt;Decreased Mi in Tiotropium group&lt;BR&gt;&lt;BR&gt;final advice to COPD patients&lt;BR&gt;&lt;BR&gt;Take the drug&lt;BR&gt;</description><comments>http://biostatguide.com/2009/01/06/a-4-year-trial-of-tiotropium-in-chronic-obstructive-pulmonary-disease--a-crtique-of-this-article-uplift-trial.aspx#Comments</comments><guid isPermaLink="false">ecc26ec9-f3b6-4fd5-afb6-f8db1357ba40</guid><pubDate>Wed, 07 Jan 2009 02:59:00 GMT</pubDate></item><item><title>The standard deviation</title><link>http://biostatguide.com/2008/04/26/the-standard-deviation.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>What is standard deviation?&lt;BR&gt;&lt;BR&gt;It is the measure of spread in a data.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;The standard deviation is usually denoted with the letter σ (lower case &lt;A class=mw-redirect title="Sigma (letter)" href="http://en.wikipedia.org/wiki/Sigma_(letter)"&gt;sigma&lt;/A&gt;). It is defined as the &lt;A title="Square root" href="http://en.wikipedia.org/wiki/Square_root"&gt;square root&lt;/A&gt; of the &lt;A title=Variance href="http://en.wikipedia.org/wiki/Variance"&gt;variance&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;SPAN class=mw-headline&gt;A simple example&lt;/SPAN&gt;
&lt;P&gt;Suppose we wished to find the standard deviation of the set of the numbers 4 and 8.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Step 1:&lt;/B&gt; find the arithmetic mean (or average) of 4 and 8,&lt;/P&gt;
&lt;DL&gt;
&lt;DD&gt;&lt;SPAN class=texhtml&gt;(4 + 8) / 2 = 6.&lt;/SPAN&gt; &lt;/DD&gt;&lt;/DL&gt;
&lt;P&gt;&lt;B&gt;Step 2:&lt;/B&gt; find the deviation of each number from the mean,&lt;/P&gt;
&lt;DL&gt;
&lt;DD&gt;&lt;SPAN class=texhtml&gt;4 − 6 = − 2&lt;/SPAN&gt; 
&lt;DD&gt;&lt;SPAN class=texhtml&gt;8 − 6 = 2.&lt;/SPAN&gt; &lt;/DD&gt;&lt;/DL&gt;
&lt;P&gt;&lt;B&gt;Step 3:&lt;/B&gt; square each of the deviations (amplifying larger deviations and making negative values positive),&lt;/P&gt;
&lt;DL&gt;
&lt;DD&gt;&lt;SPAN class=texhtml&gt;( − 2)&lt;SUP&gt;2&lt;/SUP&gt; = 4&lt;/SPAN&gt;&lt;BR&gt;
&lt;DD&gt;&lt;SPAN class=texhtml&gt;2&lt;SUP&gt;2&lt;/SUP&gt; = 4.&lt;/SPAN&gt; &lt;/DD&gt;&lt;/DL&gt;
&lt;P&gt;&lt;B&gt;Step 4:&lt;/B&gt; sum the obtained squares (as a first step to obtaining an average),&lt;/P&gt;
&lt;DL&gt;
&lt;DD&gt;&lt;SPAN class=texhtml&gt;4 + 4 = 8.&lt;/SPAN&gt; &lt;/DD&gt;&lt;/DL&gt;
&lt;P&gt;&lt;B&gt;Step 5:&lt;/B&gt; divide the sum by the number of values, which here is 2 (giving an average),&lt;/P&gt;
&lt;DL&gt;
&lt;DD&gt;&lt;SPAN class=texhtml&gt;8 / 2 = 4.&lt;/SPAN&gt; &lt;/DD&gt;&lt;/DL&gt;
&lt;P&gt;&lt;B&gt;Step 6:&lt;/B&gt; take the non-negative square root of the quotient (converting squared units back to regular units),&lt;/P&gt;
&lt;DL&gt;
&lt;DD&gt;&lt;IMG class=tex alt=\sqrt{4}=2. src="http://upload.wikimedia.org/math/8/2/2/822211f970bcb7379117b2ffc151320c.png"&gt; &lt;/DD&gt;&lt;/DL&gt;
&lt;P&gt;So, the standard deviation is 2.&lt;/P&gt;</description><comments>http://biostatguide.com/2008/04/26/the-standard-deviation.aspx#Comments</comments><guid isPermaLink="false">96ccfe93-4f49-4b3a-baa4-eb7806e7cdcf</guid><pubDate>Sat, 26 Apr 2008 15:16:00 GMT</pubDate></item><item><title>The Variance</title><link>http://biostatguide.com/2008/04/26/the-variance.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;What is the variance?&lt;BR&gt;&lt;BR&gt;answer is in the comments section</description><comments>http://biostatguide.com/2008/04/26/the-variance.aspx#Comments</comments><guid isPermaLink="false">6d67b324-743b-4b15-9a63-c99fd5aab01f</guid><pubDate>Sat, 26 Apr 2008 14:44:00 GMT</pubDate></item><item><title>What is a Quantile?</title><link>http://biostatguide.com/2008/04/26/what-is-a-quantile.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;This is same as percentiles.&lt;BR&gt;It is a series of cut of points.&lt;BR&gt;It divides the group of data into groups containing equal number of observations</description><comments>http://biostatguide.com/2008/04/26/what-is-a-quantile.aspx#Comments</comments><guid isPermaLink="false">b96b8f58-dbd9-4982-bec6-5a987c4d1476</guid><pubDate>Sat, 26 Apr 2008 14:33:00 GMT</pubDate></item><item><title>Range</title><link>http://biostatguide.com/2008/04/24/range.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;What is Range?</description><comments>http://biostatguide.com/2008/04/24/range.aspx#Comments</comments><guid isPermaLink="false">85423a83-b712-440e-9df6-793c0875c896</guid><pubDate>Fri, 25 Apr 2008 02:22:00 GMT</pubDate></item><item><title>Measures of spread</title><link>http://biostatguide.com/2008/04/24/measures-of-spread.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>Range&lt;BR&gt;Quantiles&lt;BR&gt;Variance&lt;BR&gt;Standard deviation</description><comments>http://biostatguide.com/2008/04/24/measures-of-spread.aspx#Comments</comments><guid isPermaLink="false">d9d3563c-e623-4b86-b9e6-9e81d14fa022</guid><pubDate>Fri, 25 Apr 2008 02:18:00 GMT</pubDate></item><item><title>Classifying distribution by the number of the mode</title><link>http://biostatguide.com/2008/04/24/classifying-distribution-by-the-number-of-the-mode.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;Unimodal &amp;nbsp;- Distribution with one mode.&lt;BR&gt;&lt;BR&gt;Bimodal&amp;nbsp; -&amp;nbsp; Distribution with two modes.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Trimodal- Distribution with three modes.&lt;BR&gt;</description><comments>http://biostatguide.com/2008/04/24/classifying-distribution-by-the-number-of-the-mode.aspx#Comments</comments><guid isPermaLink="false">4d2493c0-496e-4f15-98a2-d9d2dc818609</guid><pubDate>Fri, 25 Apr 2008 01:48:00 GMT</pubDate></item><item><title>Computation of the Mode</title><link>http://biostatguide.com/2008/04/24/computtion-of-the-mode.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;Compute the mode of the following data set.&lt;BR&gt;&lt;BR&gt;1 3 5 7 8 9 2 4 4 3 3 2 4 3</description><comments>http://biostatguide.com/2008/04/24/computtion-of-the-mode.aspx#Comments</comments><guid isPermaLink="false">49d76c2a-c2b6-495d-a1d7-6ff09aebea16</guid><pubDate>Fri, 25 Apr 2008 01:38:00 GMT</pubDate></item><item><title>Mode</title><link>http://biostatguide.com/2008/04/24/mode.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;What is mode?</description><comments>http://biostatguide.com/2008/04/24/mode.aspx#Comments</comments><guid isPermaLink="false">b2851408-6d44-4d43-8569-64ef11d04bd0</guid><pubDate>Fri, 25 Apr 2008 01:36:00 GMT</pubDate></item><item><title>Negatively skewed</title><link>http://biostatguide.com/2008/04/24/negatively-skewed.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>This means skewed to the left.</description><comments>http://biostatguide.com/2008/04/24/negatively-skewed.aspx#Comments</comments><guid isPermaLink="false">31c55317-bb82-4a08-a486-69e33b5e6638</guid><pubDate>Fri, 25 Apr 2008 01:21:00 GMT</pubDate></item><item><title>Positively skewed</title><link>http://biostatguide.com/2008/04/24/positively-skewed.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;This means skewed to the right</description><comments>http://biostatguide.com/2008/04/24/positively-skewed.aspx#Comments</comments><guid isPermaLink="false">3deb98ce-ef39-496f-b9c5-5f01b41a1a75</guid><pubDate>Fri, 25 Apr 2008 01:20:00 GMT</pubDate></item><item><title>Distribution is symmetric</title><link>http://biostatguide.com/2008/04/24/distribution-is-symmetric.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;This means that position of the points are distributed on each side of the sample median are the same.</description><comments>http://biostatguide.com/2008/04/24/distribution-is-symmetric.aspx#Comments</comments><guid isPermaLink="false">ea7650ad-8c4c-4572-94ba-864fb2a736bf</guid><pubDate>Fri, 25 Apr 2008 01:12:00 GMT</pubDate></item><item><title>Weakness of the Median</title><link>http://biostatguide.com/2008/04/22/weakness-of-the-median.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;What is the weakness of the median?</description><comments>http://biostatguide.com/2008/04/22/weakness-of-the-median.aspx#Comments</comments><guid isPermaLink="false">7f15ef89-6f20-4323-8259-86fe8e3ba5a5</guid><pubDate>Wed, 23 Apr 2008 02:21:00 GMT</pubDate></item><item><title>Main strength of the median</title><link>http://biostatguide.com/2008/04/22/main-strength-of-the-median.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;What is the main strength of the median?</description><comments>http://biostatguide.com/2008/04/22/main-strength-of-the-median.aspx#Comments</comments><guid isPermaLink="false">71622d30-642a-4fdc-8333-9d18a3bb71ba</guid><pubDate>Wed, 23 Apr 2008 02:08:00 GMT</pubDate></item><item><title>Median</title><link>http://biostatguide.com/2008/04/22/median-2.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;Calcualte the median of the following numbers&lt;BR&gt;&lt;BR&gt;2 4 6 8 10 12</description><comments>http://biostatguide.com/2008/04/22/median-2.aspx#Comments</comments><guid isPermaLink="false">c87843bf-937f-4b4b-b1b1-7551193453b2</guid><pubDate>Wed, 23 Apr 2008 01:54:00 GMT</pubDate></item><item><title>Median</title><link>http://biostatguide.com/2008/04/22/median.aspx?ref=rss</link><dc:creator>statguru</dc:creator><description>&lt;BR&gt;calculate the median of the following data set&lt;BR&gt;&lt;BR&gt;2 4 6 8 10</description><comments>http://biostatguide.com/2008/04/22/median.aspx#Comments</comments><guid isPermaLink="false">8a331362-de89-4740-b336-e919e27a07e9</guid><pubDate>Wed, 23 Apr 2008 01:49:00 GMT</pubDate></item></channel></rss>